1. Inhibitory Antibodies
  2. Obinutuzumab

Obinutuzumab (Synonyms: GA101; Anti-Human CD20 type II, Humanized Antibody)

Cat. No.: HY-P9910
Handling Instructions

Obinutuzumab (GA101) a novel glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.

For research use only. We do not sell to patients.

Obinutuzumab Chemical Structure

Obinutuzumab Chemical Structure

CAS No. : 949142-50-1

Size Price Stock Quantity
1 mg USD 330 In-stock
Estimated Time of Arrival: December 31
5 mg USD 810 In-stock
Estimated Time of Arrival: December 31
25 mg USD 3100 In-stock
Estimated Time of Arrival: December 31
50 mg USD 4950 In-stock
Estimated Time of Arrival: December 31
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review


Obinutuzumab (GA101) a novel glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.

In Vitro

Obinutuzumab is found to be superior to rituximab and ofatumumab in the induction of direct cell death (independent of mechanical manipulation required for cell aggregate disruption formed by antibody treatment), whereas it is 10 to 1,000 times less potent in mediating CDC. Obinutuzumab shows superior activity to rituximab and ofatumumab in ADCC and whole-blood B-cell depletion assays, and is comparable with these two in ADCP. Obinutuzumab also shows slower internalization rate upon binding to CD20 than rituximab and ofatumumab[1]

In Vivo

Obinutuzumab is more active than rituximab administered at similar doses on established RL tumors. The antitumor effect of obinutuzumab against RL xenografts is dose dependent in terms of tumor growth inhibition (TGI). TGI is calculated using NCI formula at day 34 and shows values of 25, 75, and 85% for the 10, 30, and 100 mg/kg dosages of obinutuzumab, respectively. The higher doses of 30 and 100 mg/kg of obinutuzumab significantly inhibit the growth of RL tumors and result in some complete tumor remissions (10% and 30%, respectively). Tolerability of obinutuzumab with these regimens is excellent and no significant modification of body weight is observed[2]. Obinutuzumab induces a strong antitumor effect, including complete tumor remission in the SU-DHL4 model and overall superior efficacy compared with both rituximab and ofatumumab[1]. Obinutuzumab plus bendamustine achieves superior tumor growth inhibition versus rituximab plus bendamustine and shows a statistically significant effect versus the respective single treatments. Obinutuzumab plus chemotherapy is superior to the respective monotherapies[3].

Clinical Trial
Molecular Weight







Shipping with dry ice.


Please store the product under the recommended conditions in the Certificate of Analysis.

Animal Administration

Mice: For xenograft experiments, 1×106 RL cells are injected subcutaneously on day 1. Mice are randomized when a tumor becomes palpable in groups of 10 and treatment is initiated. In a first set of experiments, rituximab and obinutuzumab are used as monotherapy at different dosages twice weekly. The 5 different groups of 10 mice are: control group receiving vehicle (NaCl 0.9%), rituximab (30 mg/kg), obinutuzumab (10 mg/kg), obinutuzumab (30 mg/kg), and obinutuzumab (100 mg/kg). The treatment is administered intravenously twice a week. The mice are closely monitored regarding weight and general status[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2


ObinutuzumabGA101Anti-Human CD20 type II, Humanized AntibodyGA 101GA-101OthersInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name



Applicant Name *


Email address *

Phone number *


Organization name *

Country or Region *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.:
MCE Japan Authorized Agent: